Section Arrow
Quote
CRBP.NASDAQ
- Corbus Pharmaceuticals Holdings
Quotes are at least 15-min delayed:2024/05/04 11:07 EDT
Last
 38.77
+0.57 (+1.49%)
Day High 
39.233 
Prev. Close
38.2 
1-M High
45 
Volume 
134.69K 
Bid
27
Ask
39.49
Day Low
37.41 
Open
38.79 
1-M Low
32.0288 
Market Cap 
401.38M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 36.61 
20-SMA 38.01 
50-SMA 37.29 
52-W High 49.8699 
52-W Low 3.0334 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-10.31/-4.67
Enterprise Value
404.62M
Balance Sheet
Book Value Per Share
-0.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.318+0.0248+8.46%-- 
VAXXVaxxinity0.1411+0.0369+35.41%-- 
DNAGinkgo Bioworks Holdings0.955+0.0939+10.90%-- 
ARDXArdelyx8.72+1.93+28.42%-- 
IBRXImmunityBio9.15+0.18+2.01%-- 
Quotes are at least 15-min delayed：2024/05/04 11:07 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.